Cyclotriol
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Other names | ZK-136295; Cycloestriol; 14α,17α-Ethanoestriol; 14α,17α-Ethanoestra-1,3,5(10)-triene-3,16α,17β-triol; 14,21-Cyclo-19-norpregna-1,3,5(10)-triene-3,16α,17α-triol |
| Routes of administration |
By mouth |
| Drug class | Estrogen |
| Pharmacokinetic data | |
| Bioavailability | 40% |
| Elimination half-life | 12.3 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H26O3 |
| Molar mass | 314.425 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cyclotriol (developmental code name ZK-136295; also known as 14α,17α-ethanoestriol) is a synthetic estrogen which was studied in the 1990s and was never marketed. It is a derivative of estriol with a bridge between the C14α and C17α positions. The drug has 40% of the relative binding affinity of estradiol for the human ERα. It showed an absolute bioavailability of 40% with high interindividual variability and an elimination half-life of 12.3 hours in pharmacokinetic studies in women.